Advertisement

Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis

  • Satoshi YoshidaEmail author
Chapter

Abstract

Stevens–Johnson syndrome and toxic epidermal necrolysis are variants of a single disease because of their manifestations and pathomechanisms. Stevens–Johnson syndrome/toxic epidermal necrolysis is a severe condition within the spectrum of diseases, including erythema multiforme major, toxic epidermal necrolysis, and Stevens–Johnson syndrome, and it is characterized by extensive epidermal death and widespread blisters and erosive lesions. Two challenging cases of toxic and epidermal necrolysis and several case study questions of the Stevens–Johnson syndrome/toxic epidermal necrolysis disease spectrum are discussed.

Keywords

Stevens–Johnson syndrome Toxic epidermal necrolysis Drug-induced hypersensitive syndrome Erythema multiforme 

References

  1. 1.
    Parrillo SJ. Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Allergy Asthma Rep. 2007;7(4):243–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Hillebrand-Haverkort ME, Budding AE, bij de Vaate LA, van Agtmael MA. Mycoplasma pneumoniae infection with incomplete Stevens-Johnson syndrome. Lancet Infect Dis. 2008;8(10):586–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64(7):1134–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Roujeau JC. The spectrum of Stevens Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994; 102(1): 28S–30S.CrossRefPubMedGoogle Scholar
  6. 6.
    Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Gambichler T, Al-Muhammadi R, Boms S. Immunologically mediated photodermatoses: diagnosis and treatment. Am J Clin Dermatol. 2009;10(3):169–80.CrossRefPubMedGoogle Scholar
  8. 8.
    Redondo P, Vicente J, España A, Subira ML, De Felipe I, Quintanilla E. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol. 1996; 135(6):999–1002.CrossRefPubMedGoogle Scholar
  9. 9.
    Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, Roujeau JC. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134(4):710–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE; TEN-IVIG Study Group. Toxic epidermal necrolysis-intravenous immunoglobulin. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139(1):26–32.CrossRefPubMedGoogle Scholar
  11. 11.
    Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol. 2002; 47(4):548–52.CrossRefPubMedGoogle Scholar
  12. 12.
    Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139(1):33–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Allergy and ImmunologyJohns Hopkins Medicine International, Tokyo Midtown Medical CenterTokyoJapan

Personalised recommendations